U.S. Markets close in 1 hr 8 mins

Immunic, Inc. (IMUX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.95+0.03 (+0.34%)
As of 2:51PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.92
Open9.00
Bid8.90 x 800
Ask8.94 x 1300
Day's Range8.66 - 9.02
52 Week Range8.64 - 28.21
Volume78,667
Avg. Volume215,869
Market Cap194.657M
Beta (5Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Why Immunic Plummeted by 21% on Thursday
    Motley Fool

    Why Immunic Plummeted by 21% on Thursday

    The company announced a planned new share issue that had many investors heading to the exits, and drove the stock down by more than 21% on the day. Immunic aims to raise gross proceeds of around $45 million by selling 4.5 million shares of common stock at $10 apiece in an underwritten public offering. The underwriting syndicate, led by Piper Sandler (NYSE: PIPR), has been granted a 30-day option to buy up to an extra 675,000 shares among themselves.

  • Immunic Stock Is Trading Lower After Equity Raise Of $45M To Fund Lead Pipeline Candidates
    Benzinga

    Immunic Stock Is Trading Lower After Equity Raise Of $45M To Fund Lead Pipeline Candidates

    Immunic Inc (NASDAQ: IMUX) has priced an underwritten public offering of 4.5 million shares at per share, representing a discount of about 16% from the last close price of $11.89 on Wednesday. The gross proceeds are expected to be approximately $45 million. Underwriters have an option to purchase up to an additional 675,000 shares. The offering will close by July 19. Piper Sandler is acting as the sole book-runner for the offering. Ladenburg Thalmann & Co. Inc., Roth Capital Partners, and Aegis

  • Immunic Stock Jumps As FDA Signs Off On 2 Clinical Trial Applications
    Benzinga

    Immunic Stock Jumps As FDA Signs Off On 2 Clinical Trial Applications

    The FDA has signed off Immunic Inc's (NASDAQ: IMUX) investigational new drug application for the Phase 3 ENSURE program of lead asset IMU-838 in patients with relapsing-remitting multiple sclerosis. In addition, the FDA also gave a green signal to the company's separate IND application for the supportive Phase 2 CALLIPER trial of IMU-838 in patients with progressive multiple sclerosis (PMS). The ENSURE program comprises two Phase 3 trials designed to evaluate the efficacy, safety, and tolerabili